Hannah Barnes has written about the Pathways study as well:
https://www.newstatesman.com/politics/society/2025/02/the-new-puberty-blockers-trial-is-expensive-and-adds-little
https://archive.is/ywTk9
"But it is difficult to see, from the information we have, how this research will add to our current knowledge. Just like the existing low-quality studies that have been so roundly criticised, Pathways aims only to “Build the evidence base on the (short and medium-term) benefits and risks” of using puberty blockers. But the Cass Review identified how we do not know the long-term impact of the drugs: on neurocognitive development, psychosexual development or longer-term bone health. This is what led to NHS England ending the routine prescription of puberty blockers. It seems unlikely that any of these gaps in the evidence-base will be filled by the planned 2025 study. It seems to want to inform “any longer-term follow-up studies.” But why not do that work now?
It should be possible to answer some of the unknowns. But there have been unnecessary roadblocks. Research commissioned by the Cass Review tried to find out what had happened to around 9,000 children who had been seen at Gender Identity Development Service (Gids) – but the service itself failed to follow up any of its patients during its 35-year history. According to several freedom of information requests, up to 2,000 children may have been referred for puberty blockers during that time. The research would have helped “develop a stronger evidence base about the types of support and interventions received and longer-term outcomes”, Cass wrote, but it was “thwarted by a lack of cooperation from the adult gender services”.
To make matters worse, NHSE – having now taken on responsibility for doing this research – does not even have the required permission to even request the data from the adult clinics. In 2022, the Conservative government changed the law to make it possible for adult gender clinics to share all medical data with a small group of researchers working with the Cass Review. There seems to be a similar lack of any progress for a number of Cass’s recommendations: research does not appear to have begun on evaluating the outcomes of either talking therapy or masculinising and feminising hormones; services for 17-25 year olds have not been established, and nor has any new provision for those considering detransition."